IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate
India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimers drug development candidate.
- India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimers drug development candidate.
- JNCASRs research based on Alzheimers cell lines, identified one lead NMI molecule, TGR 63, with the potential to reduce beta amyloid (A) plaques.
- IGC acquired exclusive global rights to the molecule and plans to develop this NMI lead candidate further.
- IGC is currently in human trials with IGC-AD1 that targets neuropsychiatric symptoms associated with dementia in Alzheimers.